DaltonTx Raises £4M To Revolutionize AI-Powered Drug Discovery

Pharma has a unique opportunity to accelerate and improve discovery using AI, but building adaptive platforms requires extensive engineering and scientific expertise. DaltonTx bridges this gap with a disease- and technology-agnostic platform that integrates directly into pharma, biotech, and CRO workflows, giving teams instant access to AI-powered discovery without the need to develop it in-house.

DaltonTx was founded by Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane MBE, combining decades of hands-on expertise in drug discovery, machine learning, and software engineering.

Read Also - Dutch FoodTech Scale-up Revyve Raises €24M In Series B Round

Designed by scientists for scientists, DaltonTx goes beyond predictive modeling to drive the complete discovery cycle from raw data and model training to molecular design, synthesis, and decision-making. More than predictive, it’s adaptive: a reasoning engine that learns from every scientist, model, and experiment to continuously enhance outcomes.

DaltonTx’s platform is designed for both small molecules and biologics, making it ideal for even the most complex R&D pipelines. It fosters collaborative intelligence, letting scientists work alongside a learning engine that continuously iterates, blending human expertise with machine learning in real time.

Dr. Garry Pairaudeau explains that DaltonTx was founded to challenge the status quo. Its adaptive, AI-driven systems integrate seamlessly into scientific workflows, learn from every experiment, and provide organizations with lasting AI capabilities.

The funding will accelerate the development of these AI-powered discovery platforms, transforming R&D economics, timelines, and outcomes to bring breakthrough medicines to patients faster.

About DaltonTx

DaltonTx empowers drug discovery with adaptive, AI-driven platforms for small molecules and biologics. Designed for pharma, biotech, and CROs, our systems integrate into workflows, learn from every experiment and combine human insight with machine intelligence. Founded by scientists, DaltonTx accelerates R&D, enabling faster, more innovative development of breakthrough therapies.